Sujal Shah, Chief Executive Officer at CymaBay Therapeutics, Inc. (CBAY), sold 129,726 shares at $15.89 ($2.1M) on 2023-11-13, disclosed to the SEC on 2023-11-14.
Scheduled sale ($2.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.89 | 20,855 | $331K | 16.1% |
| 2 | $15.89 | 20,855 | $331K | 16.1% |
| 3 | $15.89 | 44,008 | $699K | 33.9% |
| 4 | $15.89 | 44,008 | $699K | 33.9% |
| Total | $15.89 avg | 129,726 | $2.1M | 100% |
| Filing → |
| CBAY | BUY | 2022-06-07 | $200K | — | Filing → |
| CBAY | BUY | 2019-10-15 | $22K | — | Filing → |
| CBAY | BUY | 2019-09-24 | $28K | — | Filing → |